ANGN - Angion down 17% after mid-stage acute kidney injury drug misses primary endpoint

Shares of Angion Biomedica (NASDAQ:ANGN) have tumbled 17% after it reported that a phase 2 trial of its cardiac-surgery associated acute kidney injury drug ANG-3777 missed its primary endpoint. That endpoint was percentage increase in serum creatinine based upon the area under the curve. Angion and its partner, Vifor Pharma (OTCPK:GNHAF), said that the candidate showed a potential benefit based on the secondary endpoint of MAKE90. They added MAKE90 has served as an approvable endpoint to regulatory agencies. This composite endpoint combines death, initiation of renal replacement therapy, or a greater than 25% decline in Estimated Glomerular Filtration Rate (eGFR) 90 days after surgery. ANG-3777 also missed its primary endpoint in a phase 3 study of kidney transplant patients at risk for developing delayed graft function.

For further details see:

Angion down 17% after mid-stage acute kidney injury drug misses primary endpoint